Is Kairos Pharma going out of business?

Kairos Pharma, LTD. (KAPA) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Kairos Pharma, LTD. (KAPA) fundamentals, assembled from SEC filings.

Five questions, kept separate

Survival - Critical

4-6 mo of estimated runway from 2026-06-30, based on $2.6M of cash and short-term investments against $6.5M of annual burn. Adjusted shares outstanding increased 30.0% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Evidence incomplete

The current price is available, but the filing does not contain enough applicable valuation evidence to interpret it.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 2 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Filing event risk: Going-Concern Warning (-8 pts)
• Shares dilution YoY: 30.05% (YoY)
• Return on Assets: -122.24%
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-21.

Price as of 2026-09-07.